Long-term follow-up of autologous hematopoietic cell transplantation for diffuse large B cell lymphoma in the rituximab era: real‑world data from a retrospective single‑center analysis.
Jiangtao Li, Fei Zhao, Long Qian, Jingjing Yin, Yazi Yang, Jiefei Bai, Chunli Zhang, Ting Wang, Ru Feng, Hui Liu
{"title":"Long-term follow-up of autologous hematopoietic cell transplantation for diffuse large B cell lymphoma in the rituximab era: real‑world data from a retrospective single‑center analysis.","authors":"Jiangtao Li, Fei Zhao, Long Qian, Jingjing Yin, Yazi Yang, Jiefei Bai, Chunli Zhang, Ting Wang, Ru Feng, Hui Liu","doi":"10.1007/s00277-025-06430-x","DOIUrl":null,"url":null,"abstract":"<p><p>Autologous stem cell transplantation (ASCT) is the standard treatment for diffuse large B-cell lymphoma (DLBCL) in certain circumstances. However, the risk factors for ASCT outcomes remain elusive. We analyzed data from 141 patients with DLBCL who underwent first ASCT in the past decade, including 19 with pre-existing autoimmune disorders (ADs). We focus on the clinical characteristics and their potential predictive roles for the long-term transplant prognosis. With a median follow-up of 50 months (interquartile range, 26.3 to 128), progression-free survival (PFS) and overall survival (OS) at 3 years were 82.8% and 90.2%, respectively. Deaths after ASCT were predominantly caused by lymphoma relapse (73.3%). Notably, ADs history was independently associated with an increased risk of all-cause mortality (Hazard Ratio [HR]: 8.38, P = 0.014) and lymphoma relapse (HR: 6.67, P = 0.026). Furthermore, disease status before ASCT, COO subtypes, lactate dehydrogenase level at diagnosis and relapse after chemotherapy were also identified as prognostic factors for both PFS and OS. These findings demonstrate ASCT as a viable treatment option for eligible patients with high-risk DLBCL and highlight the need for increased attention to lymphoma with pre-ADs.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3423-3431"},"PeriodicalIF":2.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283474/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-025-06430-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Autologous stem cell transplantation (ASCT) is the standard treatment for diffuse large B-cell lymphoma (DLBCL) in certain circumstances. However, the risk factors for ASCT outcomes remain elusive. We analyzed data from 141 patients with DLBCL who underwent first ASCT in the past decade, including 19 with pre-existing autoimmune disorders (ADs). We focus on the clinical characteristics and their potential predictive roles for the long-term transplant prognosis. With a median follow-up of 50 months (interquartile range, 26.3 to 128), progression-free survival (PFS) and overall survival (OS) at 3 years were 82.8% and 90.2%, respectively. Deaths after ASCT were predominantly caused by lymphoma relapse (73.3%). Notably, ADs history was independently associated with an increased risk of all-cause mortality (Hazard Ratio [HR]: 8.38, P = 0.014) and lymphoma relapse (HR: 6.67, P = 0.026). Furthermore, disease status before ASCT, COO subtypes, lactate dehydrogenase level at diagnosis and relapse after chemotherapy were also identified as prognostic factors for both PFS and OS. These findings demonstrate ASCT as a viable treatment option for eligible patients with high-risk DLBCL and highlight the need for increased attention to lymphoma with pre-ADs.
期刊介绍:
Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.